Calculate gabapentin dose titration schedules for neuropathic pain, seizures, and off-label uses with renal adjustments and titration planning.
Gabapentin (Neurontin) is an anticonvulsant medication widely prescribed for neuropathic pain, postherpetic neuralgia (PHN), and as adjunctive therapy for partial seizures. It is also extensively used off-label for fibromyalgia, restless leg syndrome, anxiety disorders, alcohol withdrawal, and chronic pain syndromes. Gabapentin's unique pharmacokinetics—including saturable absorption that decreases bioavailability at higher doses, exclusive renal elimination, and lack of hepatic metabolism—make precise dosing and titration particularly important.
The recommended approach for starting gabapentin is gradual titration to minimize side effects, particularly somnolence, dizziness, and ataxia. The standard initiation protocol starts with 300 mg on the evening of Day 1, increases to 300 mg twice daily on Day 2, and reaches 300 mg three times daily on Day 3, for a total of 900 mg/day. From there, the dose is increased by 300 mg/day every 1–7 days based on patient response and tolerability, up to a maximum of 3,600 mg/day divided into three doses.
This gabapentin dosage calculator generates individualized titration schedules, applies renal dose adjustments based on creatinine clearance, recommends optimal tablet combinations for each dose step, and displays effective dose ranges for each indication. It accounts for the fact that gabapentin requires significant dose reduction in renal impairment—since it is eliminated entirely by the kidneys—and provides hemodialysis supplemental dosing guidelines.
Gabapentin's unique saturable absorption and renal elimination make dosing non-trivial. This calculator automates the standard three-day titration protocol, generates day-by-day schedules to reach the target dose, applies renal adjustments, and recommends practical tablet combinations — ensuring both safety and efficacy while minimizing common side effects. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain.
Standard titration: Day 1 = 300 mg QHS, Day 2 = 300 mg BID, Day 3 = 300 mg TID (900 mg/day). Then increase by 300 mg/day every 1–7 days to target. Max dose: 3,600 mg/day (normal renal function). Renal adjustment: CrCl 30–59 → max 1,400 mg/day BID; CrCl 15–29 → max 700 mg/day QD; CrCl < 15 → max 300 mg/day QOD.
Result: Target: 1,800 mg/day (600 mg TID), reached by Day 14
Starting at 300 mg evening on Day 1, titrating up by 300 mg every few days: Day 1 = 300 mg, Day 2 = 600 mg, Day 3 = 900 mg, then increasing to 1,200 mg, 1,500 mg, and 1,800 mg (600 mg TID) by Day 14. At 75 kg, this equals 24 mg/kg/day.
Gabapentin is absorbed in the small intestine via the L-amino acid transporter system, which becomes saturated at higher doses. This means bioavailability decreases from approximately 60% at 300 mg to about 35% at 1,600 mg and further decreases at higher doses. The practical implication is that gabapentin must be given in divided doses (TID) rather than once daily to maximize absorption. The extended-release formulation (gabapentin enacarbil / Horizant) partly addresses this limitation but has different dosing parameters and is not interchangeable with immediate-release gabapentin.
For postherpetic neuralgia, landmark trials demonstrated that gabapentin at 1,800–3,600 mg/day significantly reduced pain scores versus placebo, with NNT (number needed to treat) of approximately 4–5 for meaningful pain reduction. For partial seizures, gabapentin is effective as adjunctive therapy at 900–3,600 mg/day when added to existing anticonvulsant regimens. Off-label evidence is strongest for diabetic neuropathy, fibromyalgia (though pregabalin has the FDA indication), and perioperative pain management where gabapentin has demonstrated opioid-sparing effects.
While gabapentin has a relatively benign safety profile, recent concerns include reports of respiratory depression when combined with opioids or in patients with underlying respiratory conditions, abuse potential (gabapentin is now a Schedule V controlled substance in some US states and the UK), and suicidality risk common to all anticonvulsants. Monitor for suicidal ideation, excessive sedation, peripheral edema, and weight gain. Drug levels are not routinely monitored, but can be useful in suspected non-adherence or toxicity.
The FDA-approved maximum is 3,600 mg/day divided into three doses for seizure disorders. For neuropathic pain and PHN, effective doses typically range from 1,800 to 3,600 mg/day. Due to saturable absorption, doses above 3,600 mg/day have diminishing returns.
Gradual titration minimizes central nervous system side effects including sedation, dizziness, and ataxia, which are most pronounced when gabapentin is started at full dose. Slow titration also allows the clinician to find the minimum effective dose for each patient.
Gabapentin is eliminated exclusively by the kidneys. CrCl 30–59: reduce to 400–1,400 mg/day BID. CrCl 15–29: 200–700 mg/day QD. CrCl < 15: 100–300 mg QOD. Hemodialysis removes gabapentin significantly, requiring a 125–350 mg supplemental dose after each session.
No. Abrupt discontinuation of gabapentin can cause withdrawal symptoms including anxiety, insomnia, nausea, pain, and sweating — and may precipitate seizures in patients taking it for epilepsy. Taper by no more than 300 mg/day every 3–7 days.
Gabapentin has a relatively short half-life (5–7 hours) and its intestinal absorption is saturable, meaning larger individual doses are absorbed less efficiently. Three-times-daily dosing maintains more consistent plasma levels and maximizes total bioavailable dose.
Pregabalin (Lyrica) has linear pharmacokinetics (no saturable absorption), higher bioavailability (~90% vs. ~60%), and can be dosed twice daily. It is more potent on a mg-for-mg basis. Gabapentin 300 mg TID ≈ pregabalin 75 mg BID roughly in terms of effect.